Search

Your search keyword '"Richards, Duncan"' showing total 543 results
Start Over Author "Richards, Duncan"
543 results on '"Richards, Duncan"'

2. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Author

Standing, Joseph F., Buggiotti, Laura, Guerra-Assuncao, Jose Afonso, Woodall, Maximillian, Ellis, Samuel, Agyeman, Akosua A., Miller, Charles, Okechukwu, Mercy, Kirkpatrick, Emily, Jacobs, Amy I., Williams, Charlotte A., Roy, Sunando, Martin-Bernal, Luz M., Williams, Rachel, Smith, Claire M., Sanderson, Theo, Ashford, Fiona B., Emmanuel, Beena, Afzal, Zaheer M., Shields, Adrian, Richter, Alex G., Dorward, Jienchi, Gbinigie, Oghenekome, Van Hecke, Oliver, Lown, Mark, Francis, Nick, Jani, Bhautesh, Richards, Duncan B., Rahman, Najib M., Yu, Ly-Mee, Thomas, Nicholas P. B., Hart, Nigel D., Evans, Philip, Andersson, Monique, Hayward, Gail, Hood, Kerenza, Nguyen-Van-Tam, Jonathan S., Little, Paul, Hobbs, F. D. Richard, Khoo, Saye, Butler, Christopher, Lowe, David M., and Breuer, Judith

Published
2024
Full Text
View/download PDF

3. Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Author

Moftah, Areej, Goodman, Anna, Halifax, Rob, Turnbull, Chris, Sundaralingam, Anand, Agyeman, Akosua, Shah, Divya, Brown, Julianne, Thalasselis, Chris, Woodall, Maximillian N J, Yongblah, Francis, Howell, Aleksandra, Patel, Kavil, Hussain, Iqbal, Penfold, Ruth, Hutchinson, Simon, Poonian, Satveer, Imlach, Marie, Popoola, Olajide, Irving, Greg, Pora, Alexander, Jacobsen, Nicholas, Prasad, Vibhore, Kennard, James, Prasad, Rishabh, Khan, Umar, Razzaq, Omair, Knox, Kyle, Richardson, Scot, Krasucki, Christopher, Royal, Simon, Law, Tom, Safa, Afsana, Lee, Rem, Sehdev, Satash, Lester, Nicola, Sevenoaks, Tamsin, Lewis, David, Sheikh, Aadil, Lunn, James, Short, Vanessa, Mackintosh, Claire, Singh Sidhu, Baljinder, Mathukia, Mehul, Singh, Ivor, Moore, Patrick, Soni, Yusuf, Morton, Seb, Wilson, Pete, Murphy, Daniel, Wingfield, David, Nally, Rhiannon, Wong, Michael, Ndukauba, Chinonso, Wooding, Nick, Ogundapo, Olufunto, Woods, Sharon, Okeke, Henry, Yong, Joanna, Ahmed, Tanveer, Allcock, Damien, Atherton, George, Beltran-Martinez, Adrian, Benedict, Oluseye Emmanuel, Bird, Nigel, Brennan, Laura, Burns, Gerard, Butler, Mike, Butler, Daniel, Carson-Stevens, Andrew, Cheng, Zelda, Danson, Ruth, De Kare-Silver, Nigel, Dhasmana, Devesh, Dickson, Jon, Engamba, Serge, Fisher, Stacey, Fox, Robin, Frost, Eve, Gaunt, Richard, Ghosh, Sarit, Gilkar, Ishtiaq, Granier, Steve, Packham, Alice, Dowsell, Sarah, Gulati, Radhika, Patel, Amit, Harris, Victoria, Holmes, Jane, Gbinigie-Thompson, Oghenekome, Rahman, Najib M, Richards, Duncan B, Hayward, Gail, Dorward, Jienchi, Lowe, David M, Standing, Joseph F, Breuer, Judith, Khoo, Saye, Petrou, Stavros, Hood, Kerenza, Ahmed, Haroon, Nguyen-Van-Tam, Jonathan S, Patel, Mahendra G, Saville, Benjamin R, Francis, Nick, Thomas, Nicholas P B, Evans, Philip, Dobson, Melissa, Png, May Ee, Lown, Mark, van Hecke, Oliver, Jani, Bhautesh D, Hart, Nigel D, Cureton, Lucy, Patil, Meena, Andersson, Monique, Coates, Maria, Bateman, Clare, Davies, Jennifer C, Raymundo-Wood, Ivy, Ustianowski, Andrew, Yu, Ly-Mee, Hobbs, F D Richard, Little, Paul, and Butler, Christopher C

Published
2025
Full Text
View/download PDF

4. Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Author

Hobbs, FD Richard, Gbinigie-Thompson, Oghenekome A., Shanyinde, Milensu, Yu, Ly-Mee, Harris, Victoria, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R., Berry, Nicholas S., Evans, Philip H., Thomas, Nicholas PB, Patel, Mahendra G., Richards, Duncan, Hecke, Oliver Van, Detry, Michelle A., Saunders, Christina T., Fitzgerald, Mark, Robinson, Jared, Latimer-Bell, Charlotte, Allen, Julie, Ogburn, Emma, Grabey, Jenna, de Lusignan, Simon, Andersson, Monique, Little, Paul, and Butler, Christopher C.

Published
2024
Full Text
View/download PDF

5. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Author

Hayward, Gail, Yu, Ly-Mee, Little, Paul, Gbinigie, Oghenekome, Shanyinde, Milensu, Harris, Victoria, Dorward, Jienchi, Saville, Benjamin R., Berry, Nicholas, Evans, Philip H., Thomas, Nicholas P.B., Patel, Mahendra G., Richards, Duncan, Hecke, Oliver V., Detry, Michelle A., Saunders, Christina, Fitzgerald, Mark, Robinson, Jared, Latimer-Bell, Charlotte, Allen, Julie, Ogburn, Emma, Grabey, Jenna, de Lusignan, Simon, Hobbs, FD Richard, and Butler, Christopher C.

Published
2024
Full Text
View/download PDF

7. Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs

Author

Weeratunga, Praveen, Denney, Laura, Bull, Joshua A., Repapi, Emmanouela, Sergeant, Martin, Etherington, Rachel, Vuppussetty, Chaitanya, Turner, Gareth D. H., Clelland, Colin, Woo, Jeongmin, Cross, Amy, Issa, Fadi, de Andrea, Carlos Eduardo, Melero Bermejo, Ignacio, Sims, David, McGowan, Simon, Zurke, Yasemin-Xiomara, Ahern, David J., Gamez, Eddie C., Whalley, Justin, Richards, Duncan, Klenerman, Paul, Monaco, Claudia, Udalova, Irina A., Dong, Tao, Antanaviciute, Agne, Ogg, Graham, Knight, Julian C., Byrne, Helen M., Taylor, Stephen, and Ho, Ling-Pei

Published
2023
Full Text
View/download PDF

8. COVID-19 therapeutics : Challenges and directions for the future

Author

Robinson, Philip C., Liew, David F. L., Tanner, Helen L., Grainger, John R., Dwek, Raymond A., Reisler, Ronald B., Steinman, Lawrence, Feldmann, Marc, Ho, Ling-Pei, Hussell, Tracy, Moss, Paul, Richards, Duncan, and Zitzmann, Nicole

Published
2022

9. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Author

Agyeman, Akosua A, Ahmed, Tanveer, Allcock, Damien, Beltran-Martinez, Adrian, Benedict, Oluseye E, Bird, Nigel, Brennan, Laura, Brown, Julianne, Burns, Gerard, Butler, Mike, Cheng, Zelda, Danson, Ruth, de Kare-Silver, Nigel, Dhasmana, Devesh, Dickson, Jon, Engamba, Serge, Fisher, Stacey, Fox, Robin, Frost, Eve, Gaunt, Richard, Ghosh, Sarit, Gilkar, Ishtiaq, Goodman, Anna, Granier, Steve, Howell, Aleksandra, Hussain, Iqbal, Hutchinson, Simon, Imlach, Marie, Irving, Greg, Jacobsen, Nicholas, Kennard, James, Khan, Umar, Knox, Kyle, Krasucki, Christopher, Law, Tom, Lee, Rem, Lester, Nicola, Lewis, David, Lunn, James, Mackintosh, Claire I., Mathukia, Mehul, Moore, Patrick, Morton, Seb, Murphy, Daniel, Nally, Rhiannon, Ndukauba, Chinonso, Ogundapo, Olufunto, Okeke, Henry, Patel, Amit, Patel, Kavil, Penfold, Ruth, Poonian, Satveer, Popoola, Olajide, Pora, Alexander, Prasad, Vibhore, Prasad, Rishabh, Razzaq, Omair, Richardson, Scot, Royal, Simon, Safa, Afsana, Sehdev, Satash, Sevenoaks, Tamsin, Shah, Divya, Sheikh, Aadil, Short, Vanessa, Sidhu, Baljinder S, Singh, Ivor, Soni, Yusuf, Thalasselis, Chris, Wilson, Pete, Wingfield, David, Wong, Michael, Woodall, Maximillian N J, Wooding, Nick, Woods, Sharon, Yong, Joanna, Yongblah, Francis, Zafar, Azhar, Butler, Christopher C, Hobbs, F D Richard, Gbinigie, Oghenekome A, Rahman, Najib M, Hayward, Gail, Richards, Duncan B, Dorward, Jienchi, Lowe, David M, Standing, Joseph F, Breuer, Judith, Khoo, Saye, Petrou, Stavros, Hood, Kerenza, Nguyen-Van-Tam, Jonathan S, Patel, Mahendra G, Saville, Benjamin R, Marion, Joe, Ogburn, Emma, Allen, Julie, Rutter, Heather, Francis, Nick, Thomas, Nicholas P B, Evans, Philip, Dobson, Melissa, Madden, Tracie-Ann, Holmes, Jane, Harris, Victoria, Png, May Ee, Lown, Mark, van Hecke, Oliver, Detry, Michelle A, Saunders, Christina T, Fitzgerald, Mark, Berry, Nicholas S, Mwandigha, Lazaro, Galal, Ushma, Mort, Sam, Jani, Bhautesh D, Hart, Nigel D, Ahmed, Haroon, Butler, Daniel, McKenna, Micheal, Chalk, Jem, Lavallee, Layla, Hadley, Elizabeth, Cureton, Lucy, Benysek, Magdalena, Andersson, Monique, Coates, Maria, Barrett, Sarah, Bateman, Clare, Davies, Jennifer C, Raymundo-Wood, Ivy, Ustianowski, Andrew, Carson-Stevens, Andrew, Yu, Ly-Mee, and Little, Paul

Published
2023
Full Text
View/download PDF

11. Developing generic clinical trial animated explainer videos in the UK: results of a survey and case study.

Author

Calvert, Clare, Barber, Vicki S., Appelbe, Duncan, Sprange, Kirsty, Nollett, Claire, Lugg-Widger, Fiona, Tanner, Samantha, and Richards, Duncan B.

Abstract

Background: Animated short videos used to explain a concept or project are often called animated explainer videos (AEVs). AEVs can supplement or provide an alternative to participant information sheets as a means of giving information about clinical research to potential participants. Current use of AEVs tends to focus on the specifics of a particular trial, yet there are many common aspects of clinical research regardless of the interventions being investigated that can be poorly covered in current trial materials. The EXPLAIN initiative aimed to determine the top generic clinical trial topics considered most important by different UK trial stakeholders. The top three topics were then turned into AEVs and have been made freely available for use. Method: A list of generic clinical trial topics which often need explaining to potential trial participants when they are approached to take part in research was developed. Using a two-round Delphi survey of stakeholder groups (trial participants, patients, members of the public, site staff and clinical trials unit staff), the list of topics was expanded and prioritised to identify the topics most in need of clear explanation. The top three topics formed the basis of three AEVs, co-developed with patient and public partners. Results: Two hundred twenty-eight responses were received to the first round of the Delphi survey, and 167 of these respondents also completed the second round of the survey. The three topics prioritised for creation of animated explainer videos were as follows: (1) What is consent? (2) Who decides what treatment I get/What is randomisation? (3) Is it safe to take part in a trial/How do you know a trial is safe? Following virtual meetings with patient and public partners recruited from the Delphi respondents, a script for each AEV was co-produced before being developed into an AEV by a company specialising in animated video production. Conclusion: There are a wide range of generic concepts in which the use of animated explainer videos could be useful to improve participant understanding of clinical research. Via consensus survey across multiple stakeholders, we have determined a hierarchy of the importance of explaining these concepts. We envisage that the three AEVs created from this project will form the basis of a readily accessible library of animations to be utilised by trialists. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

12. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Author

Williams, Bryan, Turner, Rebecca, Libri, Vincenzo, Mussai, Francis, Middleton, Gary, Bowden, Sarah, Bangash, Mansoor, Gao-Smith, Fang, Patel, Jaimin, Sapey, Elizabeth, Thomas, Mark, Coles, Mark, Watkinson, Peter, Rahman, Naj, Angus, Brian, Mentzer, Alexander J., Novak, Alex, Feldman, Marc, Richter, Alex, Faustini, Sian, Bathurst, Camilla, Van de Wiel, Joseph, Mee, Susie, James, Karen, Rahman, Bushra, Turner, Karen, Hill, Adam, Gordon, Anthony, Yap, Christina, Matthay, Michael, McAuley, Danny, Hall, Andrew, Dark, Paul, McMichael, Andrew, Fisher, Benjamin A, Veenith, Tonny, Slade, Daniel, Gaskell, Charlotte, Rowland, Matthew, Whitehouse, Tony, Scriven, James, Parekh, Dhruv, Balasubramaniam, Madhu S, Cooke, Graham, Morley, Nick, Gabriel, Zoe, Wise, Matthew P, Porter, Joanna, McShane, Helen, Ho, Ling-Pei, Newsome, Philip N, Rowe, Anna, Sharpe, Rowena, Thickett, David R, Bion, Julian, Gates, Simon, Richards, Duncan, and Kearns, Pamela

Published
2022
Full Text
View/download PDF

13. Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes

Author

Shariq, Omair A., Lines, Kate E., English, Katherine A., Jafar-Mohammadi, Bahram, Prentice, Philippa, Casey, Ruth, Challis, Benjamin G., Selberherr, Andreas, Boon, Hannah, Cranston, Treena, Ryan, Fiona J., Mihai, Radu, Healy, Ultan, Kurzawinski, Tom, Dattani, Mehul T., Bancos, Irina, Dy, Benzon M., Lyden, Melanie L., Young, William F., Jr., McKenzie, Travis J., Richards, Duncan, and Thakker, Rajesh V.

Published
2022
Full Text
View/download PDF

14. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Author

Hinks, Timothy S C, Cureton, Lucy, Knight, Ruth, Wang, Ariel, Cane, Jennifer L, Barber, Vicki S, Black, Joanna, Dutton, Susan J, Melhorn, James, Jabeen, Maisha, Moss, Phil, Garlapati, Rajendar, Baron, Tanya, Johnson, Graham, Cantle, Fleur, Clarke, David, Elkhodair, Samer, Underwood, Jonathan, Lasserson, Daniel, Pavord, Ian D, Morgan, Sophie, and Richards, Duncan

Published
2021
Full Text
View/download PDF

16. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Author

Wechalekar, Ashutosh, Antoni, Gunnar, Al Azzam, Wasfi, Bergström, Mats, Biswas, Swethajit, Chen, Chao, Cheriyan, Joseph, Cleveland, Matthew, Cookson, Louise, Galette, Paul, Janiczek, Robert L., Kwong, Raymond Y., Lukas, Mary Ann, Millns, Helen, Richards, Duncan, Schneider, Ian, Solomon, Scott D., Sörensen, Jens, Storey, James, Thompson, Douglas, van Dongen, Guus, Vugts, Danielle J., Wall, Anders, Wikström, Gerhard, and Falk, Rodney H.

Published
2022
Full Text
View/download PDF

17. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Author

Yu, Ly-Mee, Bafadhel, Mona, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R, Gbinigie, Oghenekome, van Hecke, Oliver, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas PB, Patel, Mahendra G, Richards, Duncan, Berry, Nicholas, Detry, Michelle A, Saunders, Christina T, Fitzgerald, Mark, Harris, Victoria, Shanyinde, Milensu, de Lusignan, Simon, Andersson, Monique I, Barnes, Peter J, Russell, Richard EK, Nicolau, Dan V, Ramakrishnan, Sanjay, Hobbs, FD Richard, Butler, Christopher C, Van Hecke, Oliver, Thomas, Nicholas P B, Saunders, Christina, Russell, Richard E K, Nicolau, Dan V, Jr, and Hobbs, F D Richard

Published
2021
Full Text
View/download PDF

20. Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Author

Harris, Victoria, Holmes, Jane, Gbinigie-Thompson, Oghenekome, Rahman, Najib M., Richards, Duncan B., Hayward, Gail, Dorward, Jienchi, Lowe, David M., Standing, Joseph F., Breuer, Judith, Khoo, Saye, Petrou, Stavros, Hood, Kerenza, Ahmed, Haroon, Carson-Stevens, Andrew, Nguyen-Van-Tam, Jonathan S., Patel, Mahendra G., Saville, Benjamin R., Francis, Nick, Thomas, Nicholas P.B., Evans, Philip, Dobson, Melissa, Png, May Ee, Lown, Mark, van Hecke, Oliver, Jani, Bhautesh D., Hart, Nigel D., Butler, Daniel, Cureton, Lucy, Patil, Meena, Andersson, Monique, Coates, Maria, Bateman, Clare, Davies, Jennifer C., Raymundo-Wood, Ivy, Ustianowski, Andrew, Yu, Ly Mee, Hobbs, F. D.Richard, Little, Paul, Butler, Christopher C., PANORAMIC Trial Collaborative Group, Moftah, Areej, Goodman, Anna, Halifax, Rob, Turnbull, Chris, Sundaralingam, Anand, Agyeman, Akosua, Shah, Divya, Brown, Julianne, Thalasselis, Chris, Woodall, Maximillian NJ, Yongblah, Francis, Howell, Aleksandra, Patel, Kavil, Hussain, Iqbal, Penfold, Ruth, Hutchinson, Simon, Poonian, Satveer, Imlach, Marie, Popoola, Olajide, Irving, Greg, Pora, Alexander, Jacobsen, Nicholas, Prasad, Vibhore, Kennard, James, Prasad, Rishabh, Khan, Umar, Razzaq, Omair, Knox, Kyle, Richardson, Scot, Krasucki, Christopher, Royal, Simon, Law, Tom, Safa, Afsana, Lee, Rem, Sehdev, Satash, Lester, Nicola, Sevenoakes, Tamsin, Lewis, David, Sheikh, Aadil, Lunn, James, Short, Vanessa, Mackintosh, Claire, Sidhu, Baljinder Singh, Mathukia, Mehul, Singh, Ivor, Moore, Patrick, Soni, Yusuf, Morton, Seb, Wilson, Pete, Murphy, Daniel, Wingfield, David, Nally, Rhiannon, Wong, Michael, Ndukauba, Chinonso, Wooding, Nick, Ogundapo, Olufunto, Woods, Sharon, Okeke, Henry, Yong, Joanna, Ahmed, Tanveer, Allcock, Damien, Atherton, George, Beltran-Martinez, Adrian, Benedict, Oluseye Emmanuel, Bird, Nigel, Brennan, Laura, Burns, Gerard, Butler, Mike, Cheng, Zelda, Danson, Ruth, Kare-Silver, Nigel De, Dhasmana, Devesh, Dickson, Jon, Engamba, Serge, Fisher, Stacey, Fox, Robin, Frost, Eve, Gaunt, Richard, Ghosh, Sarit, Gilkar, Ishtiaq, Granier, Steve, Packman, Alice, Dowsell, Sarah, Gulati, Radhika, Patel, Amit, Harris, Victoria, Holmes, Jane, Gbinigie-Thompson, Oghenekome, Rahman, Najib M., Richards, Duncan B., Hayward, Gail, Dorward, Jienchi, Lowe, David M., Standing, Joseph F., Breuer, Judith, Khoo, Saye, Petrou, Stavros, Hood, Kerenza, Ahmed, Haroon, Carson-Stevens, Andrew, Nguyen-Van-Tam, Jonathan S., Patel, Mahendra G., Saville, Benjamin R., Francis, Nick, Thomas, Nicholas P.B., Evans, Philip, Dobson, Melissa, Png, May Ee, Lown, Mark, van Hecke, Oliver, Jani, Bhautesh D., Hart, Nigel D., Butler, Daniel, Cureton, Lucy, Patil, Meena, Andersson, Monique, Coates, Maria, Bateman, Clare, Davies, Jennifer C., Raymundo-Wood, Ivy, Ustianowski, Andrew, Yu, Ly Mee, Hobbs, F. D.Richard, Little, Paul, Butler, Christopher C., PANORAMIC Trial Collaborative Group, Moftah, Areej, Goodman, Anna, Halifax, Rob, Turnbull, Chris, Sundaralingam, Anand, Agyeman, Akosua, Shah, Divya, Brown, Julianne, Thalasselis, Chris, Woodall, Maximillian NJ, Yongblah, Francis, Howell, Aleksandra, Patel, Kavil, Hussain, Iqbal, Penfold, Ruth, Hutchinson, Simon, Poonian, Satveer, Imlach, Marie, Popoola, Olajide, Irving, Greg, Pora, Alexander, Jacobsen, Nicholas, Prasad, Vibhore, Kennard, James, Prasad, Rishabh, Khan, Umar, Razzaq, Omair, Knox, Kyle, Richardson, Scot, Krasucki, Christopher, Royal, Simon, Law, Tom, Safa, Afsana, Lee, Rem, Sehdev, Satash, Lester, Nicola, Sevenoakes, Tamsin, Lewis, David, Sheikh, Aadil, Lunn, James, Short, Vanessa, Mackintosh, Claire, Sidhu, Baljinder Singh, Mathukia, Mehul, Singh, Ivor, Moore, Patrick, Soni, Yusuf, Morton, Seb, Wilson, Pete, Murphy, Daniel, Wingfield, David, Nally, Rhiannon, Wong, Michael, Ndukauba, Chinonso, Wooding, Nick, Ogundapo, Olufunto, Woods, Sharon, Okeke, Henry, Yong, Joanna, Ahmed, Tanveer, Allcock, Damien, Atherton, George, Beltran-Martinez, Adrian, Benedict, Oluseye Emmanuel, Bird, Nigel, Brennan, Laura, Burns, Gerard, Butler, Mike, Cheng, Zelda, Danson, Ruth, Kare-Silver, Nigel De, Dhasmana, Devesh, Dickson, Jon, Engamba, Serge, Fisher, Stacey, Fox, Robin, Frost, Eve, Gaunt, Richard, Ghosh, Sarit, Gilkar, Ishtiaq, Granier, Steve, Packman, Alice, Dowsell, Sarah, Gulati, Radhika, and Patel, Amit

Abstract

Background: No randomised controlled trials have yet reported on the effectiveness of molnupiravir on longer term outcomes for COVID-19. The PANORAMIC trial found molnupiravir reduced time to recovery in acute COVID-19 over 28 days. We aimed to report the effect of molnupiravir treatment for COVID-19 on wellbeing, severe and persistent symptoms, new infections, health care and social service use, medication use, and time off work at 3 months and 6 months post-randomisation. Methods: This study is a follow-up to the main analysis, which was based on the first 28 days of follow-up and has been previously reported. For this multicentre, primary care, open-label, multi-arm, prospective randomised controlled trial conducted in the UK, participants were eligible if aged at least 50 years, or at least 18 years with a comorbidity, and unwell 5 days or less with confirmed COVID-19 in the community. Participants were randomly assigned to the usual care group or molnupiravir group plus usual care (800 mg twice a day for 5 days), which was stratified by age (<50 years or ≥50 years) and vaccination status (at least one dose: yes or no). The primary outcome was hospitalisation or death (or both) at 28 days; all longer term outcomes were considered to be secondary outcomes and included self-reported ratings of wellness (on a scale of 0–10), experiencing any symptom (fever, cough, shortness of breath, fatigue, muscle ache, nausea and vomiting, diarrhoea, loss of smell or taste, headache, dizziness, abdominal pain, and generally feeling unwell) rated as severe (moderately bad or major problem) or persistent, any health and social care use, health-related quality of life (measured by the EQ-5D-5L), time off work or school, new infections, and hospitalisation. Findings: Between Dec 8, 2021, and April 27, 2022, 25 783 participants were randomly assigned to the molnupiravir plus usual care group (n=12 821) or usual care group (n=12 962). Long-term follow-up data were available for

Published
2024

21. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Author

Kawano-Dourado, Leticia, Kulkarni, Tejaswini, Ryerson, Christopher J, Rivera-Ortega, Pilar, Baldi, Bruno Guede, Chaudhuri, Nazia, Funke-Chambour, Manuela, Hoffmann-Vold, Anna-Maria, Johannson, Kerri A, Khor, Yet Hong, Montesi, Sydney B, Piccari, Lucilla, Prosch, Helmut, Molina-Molina, María, Sellares Torres, Jacobo, Bauer-Ventura, Iazsmin, Rajan, Sujeet, Jacob, Joseph, Richards, Duncan, Spencer, Lisa G, Wendelberger, Barbara, Jensen, Tom, Quintana, Melanie, Kreuter, Michael, Gordon, Anthony C, Martinez, Fernando J, Kaminski, Naftali, Cornelius, Victoria, Lewis, Roger, Adams, Wendy, Jenkins, Gisli, Richeldi, Luca, Richeldi, Luca (ORCID:0000-0001-8594-1448), Kawano-Dourado, Leticia, Kulkarni, Tejaswini, Ryerson, Christopher J, Rivera-Ortega, Pilar, Baldi, Bruno Guede, Chaudhuri, Nazia, Funke-Chambour, Manuela, Hoffmann-Vold, Anna-Maria, Johannson, Kerri A, Khor, Yet Hong, Montesi, Sydney B, Piccari, Lucilla, Prosch, Helmut, Molina-Molina, María, Sellares Torres, Jacobo, Bauer-Ventura, Iazsmin, Rajan, Sujeet, Jacob, Joseph, Richards, Duncan, Spencer, Lisa G, Wendelberger, Barbara, Jensen, Tom, Quintana, Melanie, Kreuter, Michael, Gordon, Anthony C, Martinez, Fernando J, Kaminski, Naftali, Cornelius, Victoria, Lewis, Roger, Adams, Wendy, Jenkins, Gisli, Richeldi, Luca, and Richeldi, Luca (ORCID:0000-0001-8594-1448)

Abstract

Background: Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in the last 10 years, current regulatory-approved management approaches are limited to two therapies that prevent the progression of fibrosis. The drug development pipeline is long and there is an urgent need to accelerate this process. This manuscript introduces the concept and design of an innovative research approach to drug development in fILD: a global Randomised Embedded Multifactorial Adaptive Platform in fILD (REMAP-ILD). Methods: Description of the REMAP-ILD concept and design: the specific terminology, design characteristics (multifactorial, adaptive features, statistical approach), target population, interventions, outcomes, mission and values, and organisational structure. Results: The target population will be adult patients with fILD, and the primary outcome will be a disease progression model incorporating forced vital capacity and mortality over 12 months. Responsive adaptive randomisation, prespecified thresholds for success and futility will be used to assess the effectiveness and safety of interventions. REMAP-ILD embraces the core values of diversity, equity, and inclusion for patients and researchers, and prioritises an open-science approach to data sharing and dissemination of results. Conclusion: By using an innovative and efficient adaptive multi-interventional trial platform design, we aim to accelerate and improve care for patients with fILD. Through worldwide collaboration, novel analytical methodology and pragmatic trial delivery, REMAP-ILD aims to overcome major limitations associated with conventional randomised controlled trial approaches to rapidly improve the care of people living with fILD.

Published
2024

22. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Author

Kawano-Dourado, Leticia; https://orcid.org/0000-0003-0784-1331, Kulkarni, Tejaswini; https://orcid.org/0000-0002-4251-4988, Ryerson, Christopher J, Rivera-Ortega, Pilar, Baldi, Bruno Guedes; https://orcid.org/0000-0002-9609-5117, Chaudhuri, Nazia, Funke-Chambour, Manuela, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, Johannson, Kerri A; https://orcid.org/0000-0003-1205-5511, Khor, Yet Hong; https://orcid.org/0000-0002-5434-9342, Montesi, Sydney B, Piccari, Lucilla; https://orcid.org/0000-0002-2241-7523, Prosch, Helmut, Molina-Molina, María, Sellares Torres, Jacobo; https://orcid.org/0000-0001-6047-1670, Bauer-Ventura, Iazsmin, Rajan, Sujeet, Jacob, Joseph; https://orcid.org/0000-0002-8054-2293, Richards, Duncan; https://orcid.org/0000-0002-8093-7084, Spencer, Lisa G, Wendelberger, Barbara, Jensen, Tom, Quintana, Melanie, Kreuter, Michael, Gordon, Anthony C; https://orcid.org/0000-0002-0419-547X, Martinez, Fernando J, Kaminski, Naftali; https://orcid.org/0000-0001-5917-4601, Cornelius, Victoria, Lewis, Roger, Adams, Wendy, Jenkins, Gisli, Kawano-Dourado, Leticia; https://orcid.org/0000-0003-0784-1331, Kulkarni, Tejaswini; https://orcid.org/0000-0002-4251-4988, Ryerson, Christopher J, Rivera-Ortega, Pilar, Baldi, Bruno Guedes; https://orcid.org/0000-0002-9609-5117, Chaudhuri, Nazia, Funke-Chambour, Manuela, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, Johannson, Kerri A; https://orcid.org/0000-0003-1205-5511, Khor, Yet Hong; https://orcid.org/0000-0002-5434-9342, Montesi, Sydney B, Piccari, Lucilla; https://orcid.org/0000-0002-2241-7523, Prosch, Helmut, Molina-Molina, María, Sellares Torres, Jacobo; https://orcid.org/0000-0001-6047-1670, Bauer-Ventura, Iazsmin, Rajan, Sujeet, Jacob, Joseph; https://orcid.org/0000-0002-8054-2293, Richards, Duncan; https://orcid.org/0000-0002-8093-7084, Spencer, Lisa G, Wendelberger, Barbara, Jensen, Tom, Quintana, Melanie, Kreuter, Michael, Gordon, Anthony C; https://orcid.org/0000-0002-0419-547X, Martinez, Fernando J, Kaminski, Naftali; https://orcid.org/0000-0001-5917-4601, Cornelius, Victoria, Lewis, Roger, Adams, Wendy, and Jenkins, Gisli

Abstract

BACKGROUND Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in the last 10 years, current regulatory-approved management approaches are limited to two therapies that prevent the progression of fibrosis. The drug development pipeline is long and there is an urgent need to accelerate this process. This manuscript introduces the concept and design of an innovative research approach to drug development in fILD: a global Randomised Embedded Multifactorial Adaptive Platform in fILD (REMAP-ILD). METHODS Description of the REMAP-ILD concept and design: the specific terminology, design characteristics (multifactorial, adaptive features, statistical approach), target population, interventions, outcomes, mission and values, and organisational structure. RESULTS The target population will be adult patients with fILD, and the primary outcome will be a disease progression model incorporating forced vital capacity and mortality over 12 months. Responsive adaptive randomisation, prespecified thresholds for success and futility will be used to assess the effectiveness and safety of interventions. REMAP-ILD embraces the core values of diversity, equity, and inclusion for patients and researchers, and prioritises an open-science approach to data sharing and dissemination of results. CONCLUSION By using an innovative and efficient adaptive multi-interventional trial platform design, we aim to accelerate and improve care for patients with fILD. Through worldwide collaboration, novel analytical methodology and pragmatic trial delivery, REMAP-ILD aims to overcome major limitations associated with conventional randomised controlled trial approaches to rapidly improve the care of people living with fILD.

Published
2024

23. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Author

Kawano-Dourado, Leticia, primary, Kulkarni, Tejaswini, additional, Ryerson, Christopher J, additional, Rivera-Ortega, Pilar, additional, Baldi, Bruno Guedes, additional, Chaudhuri, Nazia, additional, Funke-Chambour, Manuela, additional, Hoffmann-Vold, Anna-Maria, additional, Johannson, Kerri A, additional, Khor, Yet Hong, additional, Montesi, Sydney B, additional, Piccari, Lucilla, additional, Prosch, Helmut, additional, Molina-Molina, María, additional, Sellares Torres, Jacobo, additional, Bauer-Ventura, Iazsmin, additional, Rajan, Sujeet, additional, Jacob, Joseph, additional, Richards, Duncan, additional, Spencer, Lisa G, additional, Wendelberger, Barbara, additional, Jensen, Tom, additional, Quintana, Melanie, additional, Kreuter, Michael, additional, Gordon, Anthony C, additional, Martinez, Fernando J, additional, Kaminski, Naftali, additional, Cornelius, Victoria, additional, Lewis, Roger, additional, Adams, Wendy, additional, and Jenkins, Gisli, additional

Published
2024
Full Text
View/download PDF

24. Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

Author

Png, May Ee, primary, Harris, Victoria, additional, Grabey, Jenna, additional, Hart, Nigel David, additional, Jani, Bhautesh Dinesh, additional, Butler, Daniel, additional, Carson-Stevens, Andrew, additional, Coates, Maria, additional, Cureton, Lucy, additional, Dobson, Melissa, additional, Dorward, Jienchi, additional, Evans, Philip, additional, Francis, Nick, additional, Gbinigie, Oghenekome Abisoye, additional, Hayward, Gail, additional, Holmes, Jane, additional, Hood, Kerenza, additional, Khoo, Saye, additional, Ahmed, Haroon, additional, Lown, Mark, additional, Mckenna, Micheal, additional, Mort, Sam, additional, Nguyen-Van-Tam, Jonathan, additional, Rahman, Najib, additional, Richards, Duncan B, additional, Thomas, Nicholas, additional, van Hecke, Oliver, additional, Hobbs, FD Richard, additional, Little, Paul, additional, Yu, Ly-mee, additional, Butler, Christopher C., additional, and Petrou, Stavros, additional

Published
2024
Full Text
View/download PDF

25. Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six Months

Author

Harris, Victoria, primary, Holmes, Jane, additional, Gbinigie, Oghenekome, additional, Rahman, Najib M., additional, Richards, Duncan, additional, Hayward, Gail, additional, Dorward, Jienchi, additional, Lowe, David, additional, Standing, Joseph, additional, Breuer, Judith, additional, Khoo, Saye, additional, Petrou, Stavros, additional, Hood, Kerenza, additional, Ahmed, Haroon, additional, Carson-Stevens, Andrew, additional, Nguyen-Van-Tam, Jonathan, additional, Patel, Mahendra, additional, Saville, Benjamin, additional, Francis, Nick, additional, Thomas, Nicholas BP, additional, Evans, Philip, additional, Dobson, Melissa, additional, Png, May Ee, additional, Lown, Mark, additional, van Hecke, Oliver, additional, Jani, Bhautesh, additional, Hart, Nigel, additional, Butler, Daniel, additional, Cureton, Lucy, additional, Patil, Meena, additional, Andersson, Monique, additional, Coates, Maria, additional, Williams, Sarah, additional, Bateman, Clare, additional, Davies, Jennifer, additional, Raymundo-Wood, Ivy, additional, Ustianowski, Andrew, additional, Yu, Ly-Mee, additional, Hobbs, F.D. Richard, additional, Little, Paul, additional, Butler, Christopher, additional, and Group, PANORAMIC Trial Collaborative, additional

Published
2024
Full Text
View/download PDF

26. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2.

Author

Higham, Helen E., Morgan, Lauren, Cooper, Cushla, Marshall, Julia, Mawer, Andrew, Jackson, Susan, Lopez‐Ramon, Raquel, Hughes, Eileen, Richards, Duncan, McShane, Helen, and Fullerton, James N.

Subjects
EXPERIMENTAL medicine, SARS-CoV-2, INFECTION control, PILOT projects, SAFETY factor in engineering
Abstract

Aims: The influence of human factors on safety in healthcare settings is well established, with targeted interventions reducing risk and enhancing team performance. In experimental and early phase clinical research participant safety is paramount and safeguarded by guidelines, protocolized care and staff training; however, the real‐world interaction and implementation of these risk‐mitigating measures has never been subjected to formal system‐based assessment. Methods: Independent structured observations, systematic review of study documents, and interviews and focus groups were used to collate data on three key tasks undertaken in a clinical research facility (CRF) during a SARS CoV‐2 controlled human infection model (CHIM) study. The Systems Engineering Initiative for Patient Safety (SEIPS) was employed to analyse and categorize findings, and develop recommendations for safety interventions. Results: High levels of team functioning and a clear focus on participant safety were evident throughout the study. Despite this, latent risks in both study‐specific and CRF work systems were identified in all four SEIPS domains (people, environment, tasks and tools). Fourteen actionable recommendations were generated collaboratively. These included inter‐organization and inter‐study standardization, optimized checklists for safety critical tasks, and use of simulation for team training and exploration of work systems. Conclusions: This pioneering application of human factors techniques to analyse work systems during the conduct of research in a CRF revealed risks unidentified by routine review and appraisal, and despite international guideline adherence. SEIPS may aid categorization of system problems and the formulation of recommendations that reduce risk and mitigate potential harm applicable across a trials portfolio. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Author

Ooms, Alexander, primary, Al-Mossawi, Hussein, additional, Bennett, Louise, additional, Bogale, Mimi, additional, Bowness, Paul, additional, Francis, Anne, additional, Goodyear, Carl, additional, Kirkham, Bruce W, additional, Lalnunhlimi, Sylvine, additional, McInnes, Iain B, additional, Richards, Duncan, additional, Siebert, Stefan, additional, Taams, Leonie S, additional, Tulunay Virlan, Aysin, additional, Yager, Nicole, additional, and Coates, Laura C, additional

Published
2023
Full Text
View/download PDF

31. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Author

Higham, Helen, primary, Morgan, Lauren, additional, Cooper, Cushla, additional, Marshall, Julia, additional, Mawer, Andrew, additional, Jackson, Susan, additional, Lopez-Ramon, Raquel, additional, Hughes, Eileen, additional, Richards, Duncan, additional, McShane, Helen, additional, and Fullerton, James, additional

Published
2023
Full Text
View/download PDF

32. Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Author

Gbinigie, Oghenekome, primary, Ogburn, Emma, additional, Allen, Julie, additional, Dorward, Jienchi, additional, Dobson, Melissa, additional, Madden, Tracie-Ann, additional, Yu, Ly-Mee, additional, Lowe, David M, additional, Rahman, Najib, additional, Petrou, Stavros, additional, Richards, Duncan, additional, Hood, Kerenza, additional, Patel, Mahendra, additional, Saville, Benjamin R, additional, Marion, Joe, additional, Holmes, Jane, additional, Png, May Ee, additional, Hayward, Gail, additional, Lown, Mark, additional, Harris, Victoria, additional, Jani, Bhautesh, additional, Hart, Nigel, additional, Khoo, Saye, additional, Rutter, Heather, additional, Chalk, Jem, additional, Standing, Joseph F, additional, Breuer, Judith, additional, Lavallee, Layla, additional, Hadley, Elizabeth, additional, Cureton, Lucy, additional, Benysek, Magdalena, additional, Andersson, Monique I, additional, Francis, Nick, additional, Thomas, Nicholas P B, additional, Evans, Philip, additional, van Hecke, Oliver, additional, Koshkouei, Mona, additional, Coates, Maria, additional, Barrett, Sarah, additional, Bateman, Clare, additional, Davies, Jennifer, additional, Raymundo-Wood, Ivy, additional, Ustianowski, Andrew, additional, Nguyen-Van-Tam, Jonathan, additional, Carson-Stevens, Andrew, additional, Hobbs, Richard, additional, Little, Paul, additional, and Butler, Christopher C, additional

Published
2023
Full Text
View/download PDF

33. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Author

Butler, Christopher C, primary, Hobbs, F D Richard, additional, Gbinigie, Oghenekome A, additional, Rahman, Najib M, additional, Hayward, Gail, additional, Richards, Duncan B, additional, Dorward, Jienchi, additional, Lowe, David M, additional, Standing, Joseph F, additional, Breuer, Judith, additional, Khoo, Saye, additional, Petrou, Stavros, additional, Hood, Kerenza, additional, Nguyen-Van-Tam, Jonathan S, additional, Patel, Mahendra G, additional, Saville, Benjamin R, additional, Marion, Joe, additional, Ogburn, Emma, additional, Allen, Julie, additional, Rutter, Heather, additional, Francis, Nick, additional, Thomas, Nicholas P B, additional, Evans, Philip, additional, Dobson, Melissa, additional, Madden, Tracie-Ann, additional, Holmes, Jane, additional, Harris, Victoria, additional, Png, May Ee, additional, Lown, Mark, additional, van Hecke, Oliver, additional, Detry, Michelle A, additional, Saunders, Christina T, additional, Fitzgerald, Mark, additional, Berry, Nicholas S, additional, Mwandigha, Lazaro, additional, Galal, Ushma, additional, Mort, Sam, additional, Jani, Bhautesh D, additional, Hart, Nigel D, additional, Ahmed, Haroon, additional, Butler, Daniel, additional, McKenna, Micheal, additional, Chalk, Jem, additional, Lavallee, Layla, additional, Hadley, Elizabeth, additional, Cureton, Lucy, additional, Benysek, Magdalena, additional, Andersson, Monique, additional, Coates, Maria, additional, Barrett, Sarah, additional, Bateman, Clare, additional, Davies, Jennifer C, additional, Raymundo-Wood, Ivy, additional, Ustianowski, Andrew, additional, Carson-Stevens, Andrew, additional, Yu, Ly-Mee, additional, Little, Paul, additional, Agyeman, Akosua A, additional, Ahmed, Tanveer, additional, Allcock, Damien, additional, Beltran-Martinez, Adrian, additional, Benedict, Oluseye E, additional, Bird, Nigel, additional, Brennan, Laura, additional, Brown, Julianne, additional, Burns, Gerard, additional, Butler, Mike, additional, Cheng, Zelda, additional, Danson, Ruth, additional, de Kare-Silver, Nigel, additional, Dhasmana, Devesh, additional, Dickson, Jon, additional, Engamba, Serge, additional, Fisher, Stacey, additional, Fox, Robin, additional, Frost, Eve, additional, Gaunt, Richard, additional, Ghosh, Sarit, additional, Gilkar, Ishtiaq, additional, Goodman, Anna, additional, Granier, Steve, additional, Howell, Aleksandra, additional, Hussain, Iqbal, additional, Hutchinson, Simon, additional, Imlach, Marie, additional, Irving, Greg, additional, Jacobsen, Nicholas, additional, Kennard, James, additional, Khan, Umar, additional, Knox, Kyle, additional, Krasucki, Christopher, additional, Law, Tom, additional, Lee, Rem, additional, Lester, Nicola, additional, Lewis, David, additional, Lunn, James, additional, Mackintosh, Claire I., additional, Mathukia, Mehul, additional, Moore, Patrick, additional, Morton, Seb, additional, Murphy, Daniel, additional, Nally, Rhiannon, additional, Ndukauba, Chinonso, additional, Ogundapo, Olufunto, additional, Okeke, Henry, additional, Patel, Amit, additional, Patel, Kavil, additional, Penfold, Ruth, additional, Poonian, Satveer, additional, Popoola, Olajide, additional, Pora, Alexander, additional, Prasad, Vibhore, additional, Prasad, Rishabh, additional, Razzaq, Omair, additional, Richardson, Scot, additional, Royal, Simon, additional, Safa, Afsana, additional, Sehdev, Satash, additional, Sevenoaks, Tamsin, additional, Shah, Divya, additional, Sheikh, Aadil, additional, Short, Vanessa, additional, Sidhu, Baljinder S, additional, Singh, Ivor, additional, Soni, Yusuf, additional, Thalasselis, Chris, additional, Wilson, Pete, additional, Wingfield, David, additional, Wong, Michael, additional, Woodall, Maximillian N J, additional, Wooding, Nick, additional, Woods, Sharon, additional, Yong, Joanna, additional, Yongblah, Francis, additional, and Zafar, Azhar, additional

Published
2023
Full Text
View/download PDF

35. Unbiased single cell spatial analysis localises inflammatory clusters of immature neutrophils-CD8 T cells to alveolar progenitor cells in fatal COVID-19 lungs

Author

Weeratunga, Praveen, Denney, Laura, Bull, Joshua A., Repapi, Emmanouela, Sergeant, Martin, Etherington, Rachel, Chaitanya Vuppussetty, Turner, Gareth D.H., Clelland, Colin, Cross, Amy, Issa, Fadi, De Andrea, Carlos Eduardo, Bermejo, Ignacio Melero, Sims, David, McGowan, Simon, Yasemin-Xiomara Zurke, Ahern, David J., Gamez, Eddie C, Whalley, Justin, Richards, Duncan, Klenerman, Paul, Monaca, Claudia, Udalova, Irina A., Dong, Tao, Ogg, Graham, Knight, Julian C., Byrne, Helen M., Taylor, Stephen, and Ling-Pei Ho

Subjects
Organising pnemonia, Spatial proteomics, Immune-structural interactions, Multi-Dimensional Viewer (MDV) software, Spatial analysis, Inflammatory network, Severe COVID-19 disease, COVID-19 lung disease, Diffuse alveolar damage, Spatial Omics Oxford Pipeline (SpOOx)
Abstract

Single cell spatial interrogation of the immune-structural interactions in COVID -19 lungs is challenging, mainly because of the marked cellular infiltrate and architecturally distorted microstructure. To address this, we developed a suite of mathematical tools to search for statistically significant co-locations amongst immune and structural cells identified using 37-plex imaging mass cytometry. This unbiased method revealed a cellular map interleaved with an inflammatory network of immature neutrophils, cytotoxic CD8 T cells, megakaryocytes and monocytes co-located with regenerating alveolar progenitors and endothelium. Of note, a highly active cluster of immature neutrophils and cytotoxic CD8 T cells, was found spatially linked with alveolar progenitor cells, and temporally with the diffuse alveolar damage stage. These findings provide new insights into how immune cells interact in the lungs of severe COVID-19 disease. We provide our pipeline Spatial Omics Oxford Pipeline (SpOOx)and visual-analytical tool, Multi-Dimensional Viewer (MDV) software, as a resource for spatial analysis.

Published
2022
Full Text
View/download PDF

38. Corrigendum to ‘Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes’ [Surgery 171 (2021) 77–87]

Author

Shariq, Omair A., Lines, Kate E., English, Katherine A., Jafar-Mohammadi, Bahram, Prentice, Philippa, Casey, Ruth, Challis, Benjamin G., Selberherr, Andreas, Boon, Hannah, Cranston, Treena, Ryan, Fiona J., Mihai, Radu, Healy, Ultan, Kurzawinski, Tom, Dattani, Mehul T., Bancos, Irina, Dy, Benzon M., Lyden, Melanie L., Young, William F., Jr., McKenzie, Travis J., Richards, Duncan, and Thakker, Rajesh V.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results